Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1500 participants.

Also called NCT02100228

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose supportive care
Phase
Phase 4
Enrolled
  • 1,500 participants (enrolled count) (from the registry)
Sponsor
  • Bristol-Myers Squibb Registry lists this organization as a collaborator
  • Pfizer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02100228
  • EudraCT 2014-001231-36
Other papers using this trial's data
  • Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial European heart journal, 2018-08-21 DOI, PubMed 29659797, PMC6110194 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Belgium, Canada, Denmark, Germany, Israel, Italy, Japan, Romania, South Korea, Spain, Sweden (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02100228. Randomized; no masking; primary purpose supportive care. Start 2014-07-14 (actual); primary completion 2017-02-08 (actual). Results posted on 2018-04-10.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)
Acronym
EMANATE
Intervention (Drug)
Apixaban
Intervention (Drug)
Parenteral heparin and/or oral Vitamin K antagonist
Lead sponsor
Pfizer (class: industry)
Collaborator
Bristol-Myers Squibb (class: industry)

Record details

Record id
cardio:ct-nct02100228
Content hash
14e1fcb104f052dafe21dd4834bf6ab716c873cb41dde35e08d9f5133f453943